Congressional Testimony
This section includes testimony by FDA officials before House and Senate Committees and Subcommittees. For testimony from previous years, see the FDA Archive.
Date | Testimony | Speaker | Excerpt |
---|---|---|---|
FDA User Fee Reauthorization: Ensuring Safe and Effective Drugs and Biologics - 02/03/2022 | Patrizia Cavazzoni, Peter Marks | ||
Addressing New Variants: A Federal Perspective On The Covid-19 Response - 01/11/2022 | Janet Woodcock | ||
The Overdose Crisis: Interagency Proposal to Combat Illicit Fentanyl-Related Substances - 12/02/2021 | Douglas Throckmorton | ||
Next Steps: The Road Ahead for the COVID-19 Response - 11/04/2021 | Janet Woodcock | ||
The Path Forward: Advancing Treatments and Cures for Neurodegenerative Diseases - 07/29/2021 | Patrizia Cavazzoni | ||
The Path Forward: A Federal Perspective on the COVID-19 Response - 07/20/2021 | Janet Woodcock | ||
An Epidemic Continues: Youth Vaping in America - 06/23/2021 | Janet Woodcock | ||
The President's FY2022 Budget Request for FDA - 06/10/2021 | Janet Woodcock | ||
An Update from Federal Officials on Efforts to Combat COVID-19 - 05/11/2021 | Peter Marks | ||
Examining Our Covid-19 Response: An Update From Federal Officials - 03/18/2021 | Peter Marks |